Hydroxyurea, BCL11A, and HBS1L-MYB gene variants interact to modulate fetal hemoglobin in Sickle Cell Anemia.

Sickle cell anemia (SCA), caused by an HBB gene mutation, leads to abnormal hemoglobin S and erythrocyte sickling. A key therapeutic strategy involves increasing fetal hemoglobin (HbF) levels, which dilutes HbS and reduces sickling. Hydroxyurea (HU) is a standard treatment that elevates HbF. Additionally, single-nucleotide polymorphisms (SNPs) in the BCL11A gene and the HBS1L-MYB intergenic region are known to influence HbF production. Understanding the combined impact of HU, genetic variants, and other factors on HbF variability is crucial for optimizing SCA management.

Researchers analyzed DNA from 43 individuals with sickle cell anemia (SCA) from Western Bahia, Brazil. They genotyped 7 SNPs: rs4671393, rs7557939, rs1427407, and rs11886868 within BCL11A, and rs4895441, rs9402686, and rs11759553 in the HBS1L-MYB intergenic region. The study compared HbF levels between individuals receiving Hydroxyurea (HU) therapy and untreated controls. Statistical analyses included Factorial ANOVA to assess interactions and Multiple linear regression to determine the contribution of various factors to HbF variability.